Back to Trades
Other4
Akoya Biosciences, Inc.
AKYA
Total Value
$1.1M
Company Information
- Company Name
- Akoya Biosciences, Inc.
- Ticker Symbol
- AKYA
- CIK
- 0001711933
Insider Information
- Name
- Winkler Matthew
- Role
- Director
- Location
- MARLBOROUGH, MA
Director
Filing Details
- Filing Date
- Jul 10, 2025
- Transaction Date
- Jul 8, 2025
- Accession Number
- 0001062993-25-012726
- Form Type
- 4
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Jul 8, 2025 | Common Stock | 984,513 | — | Other | — |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jul 8, 2025 | Derivative | 16,860 | $21.95 | Other | $370.1K |
| Jul 8, 2025 | Derivative | 30,549 | $11.24 | Other | $343.4K |
| Jul 8, 2025 | Derivative | 56,322 | $5.70 | Other | $321.0K |
| Jul 8, 2025 | Derivative | 50,000 | $2.01 | Other | $100.5K |
Footnotes
- (F1)Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix.
- (F2)In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement.
- (F3)Disposition of options pursuant to Merger Agreement.
- (F4)Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.